Skandinaviska Enskilda Banken AB publ Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

Skandinaviska Enskilda Banken AB publ lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 109.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 370,623 shares of the medical equipment provider’s stock after purchasing an additional 193,918 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.16% of Hologic worth $27,519,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in HOLX. Cetera Investment Advisers increased its stake in Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after acquiring an additional 13,380 shares during the last quarter. Nordea Investment Management AB raised its stake in Hologic by 1.3% during the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after purchasing an additional 19,680 shares in the last quarter. Pinebridge Investments L.P. lifted its position in Hologic by 39.8% during the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after purchasing an additional 113,050 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Hologic by 51.4% in the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after buying an additional 176,006 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Hologic by 18.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock worth $170,297,000 after buying an additional 338,212 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Down 1.2 %

Shares of HOLX opened at $81.39 on Friday. The firm has a fifty day moving average price of $80.74 and a 200-day moving average price of $77.05. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $18.99 billion, a P/E ratio of 41.53, a P/E/G ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $0.93 EPS. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI raised their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. lifted their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday. Finally, StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Insiders Place Their Bets

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at approximately $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock worth $1,469,973 in the last ninety days. 1.75% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.